Medpace (MEDP)
(Delayed Data from NSDQ)
$421.31 USD
-2.65 (-0.63%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $421.05 -0.26 (-0.06%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$421.31 USD
-2.65 (-0.63%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $421.05 -0.26 (-0.06%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth A Momentum A VGM
Zacks News
Abbott's (ABT) AVEIR DR Leadless Pacemaker System Gains CE Mark
by Zacks Equity Research
Abbott (ABT) receives a CE mark for AVEIR DR, the world's first dual chamber leadless pacemaker system.
Abbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems
by Zacks Equity Research
Abbott's (ABT) glucose monitoring systems - Lingo and Libre Rio - based on Freestyle Libre technology, receive FDA clearance.
Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes
by Zacks Equity Research
Myriad Genetics (MYGN) continues to enhance its customer targeting, digital marketing and overall operating model to drive commercial leverage in 2024 and beyond.
Charles River (CRL) Partners to Reduce Animal Research Usage
by Zacks Equity Research
Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
The latest trading day saw Medpace (MEDP) settling at $405.68, representing a +1.12% change from its previous close.
Align Technology (ALGN) Gains From New Alliances, Global Growth
by Zacks Equity Research
Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America.
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data
by Zacks Equity Research
Capricor (CAPR) anticipates announcing top-line results from the Phase 3 HOPE-3 pivotal trial by the fourth quarter of 2024.
QIAGEN (QGEN) Unveils dPCR Tool, Enhances GeneGlobe Platform
by Zacks Equity Research
QIAGEN (QGEN) launches the digital PCR Assay Design Tool for QIAcuity and expands the customization capabilities of its GeneGlobe research platform.
Here's Why Omnicell (OMCL) Should be in Your Portfolio Now
by Zacks Equity Research
A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).
5 Growth Stocks to Buy for Steady Returns in June
by Nalak Das
We have narrowed our search to five growth stocks that have solid upside left for 2024. These stocks are: APP, DDOG, MNDY, MEDP, WING.
Medtronic (MDT) Cardiovascular Business Expands Amid Macro Woes
by Zacks Equity Research
For Hugo surgical robot, Medtronic (MDT) is scaling manufacturing production, expanding regulatory approvals and ramping up installations to see continued progress internationally.
ICON (ICRL) Gains From Strategic Acquisitions, Innovation
by Zacks Equity Research
In addition to its focused efforts within the biotech segment, ICON (ICLR) continues to drive forward its leadership in large pharma.
Here's Why Thermo Fisher (TMO) Should be in Your Portfolio
by Zacks Equity Research
Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).
U.S. Services PMI Returns to Expansion Path in May: 5 Picks
by Nalak Das
We have selected five services-oriented stocks that have strong potential for the rest of 2024. These stocks are: MEDP, TXRH, WING, GS, RGA.
Henry Schein (HSIC) Banks on Global Expansion Amid Macro Issues
by Zacks Equity Research
Within the Dental business, Henry Schein (HSIC) is aiming to deliver customized solutions, leveraging market insights and technological advancements.
IDEXX (IDXX) Expands Test Menu for the Catalyst Platform
by Zacks Equity Research
IDEXX's (IDXX) new Catalyst Pancreatic Lipase Test is likely to support veterinarians globally in diagnosing pancreatitis.
QIAGEN's (QGEN) New Launch Expands US Syndromic Testing Menu
by Zacks Equity Research
QIAGEN's (QGEN) new QIAstat-Dx Gastrointestinal Panel 2 offers fast and accurate identification of up to 16 common gastrointestinal pathogens.
Top 5 Non-Tech Winners YTD With More Potential for Growth
by Nalak Das
Five Nasdaq listed non-tech stocks that have provided more than 40% returns year to date and have more potential for growth. These are: COIN, MEDP, WING, TXRH, TSCO.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM).
Zimmer Biomet (ZBH) Procedure Recovery Aids Amid Macro Woes
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to record strong procedure volume in 2024 in both the Knees and Hips businesses, banking on an improved market scenario.
Bruker (BRKR) Launches neofleX MALDI-TOF/TOF MSI System
by Zacks Equity Research
Bruker's (BRKR) neofleX is a versatile, high-performance and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers.
Medpace (MEDP) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Medpace (MEDP) reachead $389.41 at the closing of the latest trading day, reflecting a +0.79% change compared to its last close.
Omnicell (OMCL) Gains From New Offerings Amid Cost Woes
by Zacks Equity Research
With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.
QIAGEN (QGEN) Advances Precision Medicine With New QIAseq Kit
by Zacks Equity Research
QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.
Teleflex's (TFX) Urolift Drives Market Share, Macro Woes Stay
by Zacks Equity Research
The commercialization of Teleflex's (TFX) UroLift in Japan has been a significant step toward making this therapy more broadly available to men suffering from BPH.